KEYNOTE-010: flash of a supernova (immune-checkpoint inhibitors) in second-line non-small cell lung cancer

被引：2
|
作者：
Horinouchi, Hidehito [1 ]
机构：
[1] Natl Canc Ctr, Dept Thorac Oncol, Chuo Ku, 5-1-1,Tsukiji, Tokyo 1040045, Japan
来源：
JOURNAL OF THORACIC DISEASE | 2017年 / 9卷 / 11期
关键词：
OPEN-LABEL; DOCETAXEL; PEMBROLIZUMAB; NIVOLUMAB;
D O I：
10.21037/jtd.2017.10.135
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：4187 / 4190
页数：4
相关论文
共 50 条
  • [1] Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer
    Rossi, Emanuela
    Sgambato, Assunta
    De Chiara, Giovanni
    Casaluce, Francesca
    Losanno, Tania
    Sacco, Paola Claudia
    Santabarbara, Giuseppe
    Gridelli, Cesare
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (03) : 419 - 428
  • [2] Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology
    Manglaviti, Sara
    Brambilla, Marta
    Signorelli, Diego
    Ferrara, Roberto
    Lo Russo, Giuseppe
    Proto, Claudia
    Galli, Giulia
    De Toma, Alessandro
    Occhipinti, Mario
    Viscardi, Giuseppe
    Beninato, Teresa
    Zattarin, Emma
    Bini, Marta
    Lobefaro, Riccardo
    Massa, Giacomo
    Bottiglieri, Achille
    Apollonio, Giulia
    Sottotetti, Elisa
    Di Mauro, Rosa Maria
    Trevisan, Benedetta
    Ganzinelli, Monica
    Fabbri, Alessandra
    de Braud, Filippo G. M.
    Garassino, Marina Chiara
    Prelaj, Arsela
    CLINICAL LUNG CANCER, 2022, 23 (01) : E17 - E28
  • [3] Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancer
    Borgeaud, Maxime
    Friedlaender, Alex
    Addeo, Alfredo
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (11) : 2353 - 2358
  • [4] Immune checkpoint inhibitors are superior to docetaxel as second-line therapy for patients with non-small cell lung carcinoma
    Fillon, Mike
    CA-A CANCER JOURNAL FOR CLINICIANS, 2018, 68 (03) : 178 - 179
  • [5] Association Between the Type of First-Line Chemotherapy and Outcome of Second-Line Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Kim, M.
    Roh, J.
    Eom, J. S.
    Lee, M. K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S342 - S342
  • [6] Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection
    Banna, Giuseppe Luigi
    Passiglia, Francesco
    Colonese, Francesca
    Canova, Stefania
    Menis, Jessica
    Addeo, Alfredo
    Russo, Antonio
    Cortinovis, Diego Luigi
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 129 : 27 - 39
  • [7] First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
    Huang, Zhangfeng
    Su, Wenhao
    Lu, Tong
    Wang, Yuanyong
    Dong, Yanting
    Qin, Yi
    Liu, Dahai
    Sun, Lili
    Jiao, Wenjie
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [8] Current status of immune-checkpoint inhibitors in the first-line treatment of metastatic non-small cell lung cancer
    Tanaka, Kentaro
    ANNALS OF ONCOLOGY, 2019, 30 : 32 - 32
  • [9] Immune checkpoint inhibitors in non-small cell lung cancer
    Eberhardt, Wilfried Ernst Erich
    ONKOLOGE, 2017, 23 (10): : 838 - 844
  • [10] Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Herzberg, Benjamin
    Campo, Meghan J.
    Gainor, Justin F.
    ONCOLOGIST, 2017, 22 (01): : 81 - 88
12345